Fc-binding antibody-recruiting molecules exploit endogenous antibodies for anti-tumor immune responses†

Koichi Sasaki,a Minori Harada,b Yoshiki Miyashita,b Hiroshi Tagawa,b Akihiro Kishimura,abc Takeshi Mori*ab and Yoshiki Katayama*abcd

Redirecting endogenous antibodies in the bloodstream to tumor cells using synthetic molecules is a promising approach to trigger anti-tumor immune responses. However, current molecular designs only enable the use of a small fraction of endogenous antibodies, limiting the therapeutic potential. Here, we report Fc-binding antibody-recruiting molecules (Fc-ARMs) as the first example addressing this issue. Fc-ARMs are composed of an Fc-binding peptide and a targeting ligand, enabling the exploitation of endogenous antibodies through constant affinity to the Fc region of antibodies, whose sequence is conserved in contrast to the Fab region. We show that Fc-ARM targeting folate receptor-α (FR-α) redirects a clinically used antibody mixture to FR-α+ cancer cells, resulting in cancer cell lysis by natural killer cells in vitro. Fc-ARMs successfully interacted with antibodies in vivo and accumulated in tumors. Furthermore, Fc-ARMs recruited antibodies to suppress tumor growth in a mouse model. Thus, Fc-ARMs have the potential to be a novel class of cancer immunotherapeutic agents.

Introduction

Immune cells, such as natural killer (NK) cells, recognize antibodies bound to target proteins and lyse target cells, and this process is termed antibody-dependent cell-mediated cytotoxicity (ADCC). Based on immune-mediated mechanisms of action including ADCC, therapeutic IgG antibodies have revolutionized the clinical outcomes for multiple types of cancers.1 However, the potential immunogenicity of monoclonal antibodies (mAbs) is one of their limitations, causing side effects such as IgE-mediated anaphylaxis and the production of anti-drug antibodies in the clinic.2,3

As a potential solution to this issue, antibody-recruiting small molecules (ARMs) have been developed to induce antibody-mediated immune responses while circumventing antibody administration.4 ARMs are composed of an antibody-binding terminus (ABT) and a target-binding terminus (TBT) (Fig. 1A), and redirect endogenous antibodies in the bloodstream to target

† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0sc00017e

Chem. Sci., 2020, 11, 3208–3214
This journal is © The Royal Society of Chemistry 2020
cells such as tumor cells. Subsequently, recruited antibodies trigger immune responses to eliminate the target (Fig. 1B, left panel). Notably, ARMs are thought to be less immunogenic due to their small molecular size.5,6 To date, various types of TBTs have been developed.7–22 By contrast, only a few types of ABTs have shown potential utility: galactose–z,1,3-galactose (z-Gal),12,13 rhamnose,23 nitroarenes,14–16,20,22 and phosphorylcholine.23 This is because ABTs have so far been limited to antigens against endogenous antibodies present in a wide range of population.

However, these types of ABTs suffer from some shortcomings that limit their therapeutic application. For example, endogenous antibodies against ABTs are generally in short supply (e.g. anti-z-Gal accounts for ~1% of endogenous IgG in human serum24), limiting the probability of encountering ARMs and antibodies in the human body. In addition, the efficacy of ARMBased therapy may be influenced by the polyclonal affinity of endogenous antibodies to the ABT.4 Although immunization of patients with ABTs may help to improve the characteristics of anti-ABT endogenous antibodies, it increases the complexity of treatment procedures, and may also induce additional side effects. Thus, new approaches that enable the exploitation of a larger proportion of pre-existing endogenous antibodies by constant affinity would be a breakthrough for the clinical translation of ARMs.

The Fc region of an antibody is characterized by its conserved molecular structure, as well as a variety of biological functions. It is the Fc module that is responsible for ADCC in the development of biopharmaceuticals.15,26 A recent study revealed that the Fc region of an antibody binds to virus-infected cells and NK cells simultaneously, resulting in ADCC against the infected cells.27 This report indicated that ADCC could be induced independently of antigen–Fab interactions.

Previously, we reported a new class of ARMs, namely FcARMS, in which the Fc-binding cyclic peptide (Fc-III)28 is used as an ABT (Fig. 1B, right panel).29 Use of the Fc-binding peptide enables Fc-ARMS to at least access IgG1 and IgG2 with constant affinity.30 These two IgG subclasses account for more than 80% of the total IgG in humans.31,32 Thus, Fc-ARMS can theoretically exploit the majority of endogenous antibodies through their constant affinity to IgG-Fc. We previously demonstrated that Fc-ARMS can recruit human IgG on the surface of cancer cells in a selective manner.29 However, recruited antibodies did not mediate ADCC under the previous experimental conditions. Given that ADCC is regulated by the overall affinity of the antibody to its antigen33 and CD16a,34 we hypothesized that the replacement of the Fc-III peptide with a recently reported peptide, Fc-IIIC4, which has higher affinity for IgG-Fc,37 would strengthen the recruited antibody ability to activate effector cells such as NK cells for target cell destruction. We conducted quantitative evaluations of antibody recruitment and determined the anti-tumor effects of Fc-ARM both in vitro and in vivo to prove the concept of the Fc-ARM strategy.

**Results and discussion**

**Fc affinity and antibody recruitment**

We used an Fc-III peptide or Fc-IIIC4 peptide37 as an ABT and folic acid (FA) as a TBT (Fig. 1C). FA has sub-nanomolar affinity

---

**Fig. 2**  Fc-ARMS bind to both the Fc region of the antibody and FR-a for antibody recruitment to cancer cells. (A–C) Dissociation constants of (A) Fc-ARM1 and (B) Fc-ARM2 to Trastuzumab were determined by SPR measurements. (C) $k_{on}$, $k_{off}$, and $K_{d}$ values for Fc-ARMS are summarized. (D) IGROV-1 cells were seeded and incubated overnight. Fc–fluorescein (Fc-fluo, 500 nM), Fc–ARM2 (100 nM), and FA (100 μM) were used. Fc–flu, Fc–flu + Fc–ARM2, or Fc–flu + Fc–ARM2 + FA were added to the cells. After washing, the cells were stained with Hoechst 33342. Scale bar = 20 μm. Representative pictures are shown. (E) IGROV-1 cells were treated with 10 nM of Fc-ARMS and increasing concentrations of IgG-FITC from serum. The mean fluorescence intensity (MFI) derived from the recruited antibodies was quantified by flow cytometry (n = 3, mean ± SEM). Two experimental repeats were performed. Statistical analyses were carried out using a two-tailed Welch’s t test. *p < 0.05; **p < 0.01.
to folate receptor-α (FR-α) and is therefore used for targeted drug delivery and imaging of cancers overexpressing FR-α. We connected the ABT and TBT using a hexaethylene glycol linker and synthesized two types of Fc-ARMs, namely Fc-ARM1 and Fc-ARM2. The Fc-ARMs were characterized by reverse phase high performance liquid chromatography (RP-HPLC, Fig. S1†) and matrix assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS, Fig. S2†).

First, we used surface plasmon resonance (SPR) to measure the affinities between Fc-ARMs and the Fc region of the IgG1 antibody. We functionalized SPR chips with anti-HER2 humanized IgG1 mAb (Trastuzumab) and flowed Fc-ARMs over the chip surface. The results showed that Fc-ARM2 had higher affinity to IgG1 compared with Fc-ARM1 (Fig. 2A–C). The $K_d$ values were 25.0 nM for Fc-ARM1 and 6.1 nM for Fc-ARM2. Next, we verified whether Fc-ARM2 could recruit IgG on FR-α cancer cells. Fluorescence microscopy revealed that Fc-ARM2 successfully recruited FITC-labeled human IgG (IgG-FITC) to IGROV-1 cells (Fig. S3†). Excess FA diminished IgG-derived fluorescence. Furthermore, Fc-ARM2 recruited the papain-digested Fc fragment of IgG1 labeled with fluorescein (Fc-fluo) on IGROV-1 cells (Fig. 2D and S4†). These results demonstrated that the bispecific affinities of Fc-ARM2 to FR-α and the Fc region of the antibody are crucial for antibody recruitment.

Next, we conducted a quantitative evaluation of antibody recruitment using flow cytometry. Considering that 10 nM of Fc-ARM1 saturated the amount of recruited IgG (Fig. S5†), 10 nM of Fc-ARM (Fc-ARM1 or Fc-ARM2) and increasing concentrations of IgG-FITC were added to IGROV-1 cells. As a result, Fc-ARM2 recruited a higher amount of IgG-FITC compared with Fc-ARM1 (Fig. 2E). Notably, 1 μM of IgG-FITC reduced the mean fluorescence intensity (MFI), which was evident in three component systems (in our case, the ternary complex of FR-α, Fc-ARM, and IgG). These data demonstrated that Fc-ARM2 possesses improved affinity for IgG-Fc, enabling more efficient recruitment of antibodies on FR-α cancer cells.

**Tumor cell killing by mAb recruitment**

Next, we evaluated whether antibodies redirected to tumor cells by Fc-ARMs can activate NK cells and induce ADCC. Importantly, we previously reported that the binding sites of an Fc-binding peptide and CD16a to the Fc region of the antibody do not overlap, supporting the feasibility of the Fc-ARM strategy. Ofatumumab (anti-CD20 IgG1 mAb) was used as a source of antibodies since its ADCC capability is certified, and it does not bind to IGROV-1 cells by itself (IGROV-1 cells do not express CD20). IGROV-1 cells were co-cultured with human NK cells (KHYG-1/CD16a-158V) for 16 h in the presence of an Fc-ARM and anti-CD20, and then lactose dehydrogenase (LDH) released from lysed cells was quantified. Fc-ARM2 + anti-CD20 showed clear target cell killing in an effector/target (E/T) ratio-dependent manner, whereas anti-CD20 or Fc-ARM2 alone did not (Fig. 3A). Cytotoxicity was eliminated by excess FA. Upon recruitment of anti-CD20, NK cells showed secretion of interferon-γ (IFN-γ) (Fig. 3B) and surface mobilization of CD107a (an activation marker of NK cells, Fig. 3C and S6†). ADCC was not induced against A549 lung cancer cells (FR-α−) (Fig. S7†). These results clearly demonstrated that Fc-ARM-mediated antibody recruitment activates NK cells and induces ADCC.

**Fc affinity and NK cell activation**

We next verified whether or not the Fc affinity of Fc-ARMs determines the immune-stimulatory activity of recruited antibodies. Specifically, we conducted NK cell lysis assays over different co-culture time periods as well as with different antibody concentrations. After 4 h of co-culture, Fc-ARM1 + anti-CD20 did not show detectable cytotoxicity (Fig. 4A), in line with our previous report. Fc-ARM2 + anti-CD20 showed higher cytotoxicity compared with Fc-ARM1 + anti-CD20 after 6, 8, and 16 h of co-culture (Fig. 4B), and it took more incubation time for Fc-ARM1 to reach comparable % cytotoxicity with Fc-ARM2. This result is in accordance with the literature showing that antibodies with enhanced affinity to their antigen or CD16a accelerate the kinetics of ADCC. Thus,
we conclude that the reason why we could not detect ADCC using Fc-ARM1 in the previous report is insufficient incubation time. When compared with Fc-ARM1, Fc-ARM2 induced ADCC more effectively, along with increasing concentration of anti-CD20 (Fig. 4C). Similarly, Fc-ARM2 + anti-CD20 induced a higher amount of IFN-γ secretion from NK cells than Fc-ARM1 + anti-CD20 after 16 h of co-culture (Fig. S8†). Notably, the Fc-fragment of anti-CD20 induced cytotoxicity upon recruitment by Fc-ARM2 (Fig. 4D). Taken together, these data demonstrated that Fc affinity is a critical factor controlling both the efficacy and kinetics of ADCC in the Fc-ARM strategy, and that the Fab region of the antibody is not necessarily required for ADCC induction.

Partial inhibition of anti-EGFR by the recruited antibodies

Previously, we reported that Fc-ARM1 inhibited the ADCC activity of an anti-epidermal growth factor receptor (EGFR) mAb against IGROV-1 cells (EGFR/FR-α double positive). To investigate the mechanism of action, we first compared the amount of EGFR anti-EGFR binary complex with that of the ternary complex formed on IGROV-1 cells using flow cytometry. IGROV-1 cells were incubated with fluororescin-labeled anti-EGFR mAb (Cetuximab). The results showed that 5 nM of anti-EGFR mAb was sufficient to saturate binary complex formation (Fig. S9A†). Furthermore, 10 nM of Fc-ARM1 induced about a six-fold increase in MFI, showing that a substantially higher amount of the ternary complex could be formed on IGROV-1 cells compared with the binary complex. Next, we evaluated the ADCC activity of both complexes with a co-culture time of 16 h (Fig. S9B†). The binary complex of EGFR/anti-EGFR mAb showed stronger ADCC activity compared with the ternary complex (Fc-ARM2 + anti-CD20), which is reasonable considering the overall affinity of those two forms of antibodies for IGROV-1 cells (Cetuximab reportedly possesses a $K_d$ value of 0.49 nM against EGFR). Interestingly, the co-existence of the binary complex and the ternary complex (Fc-ARM2 + anti-EGFR) resulted in similar ADCC activity compared with the ternary complex (Fc-ARM2 + anti-CD20). These results indicated that the ternary complex not only activates NK cells, but also works as a competitive inhibitor of CD16a against stronger agonists (in this case, the binary complex of EGFR/anti-EGFR mAb). We do not discuss the potential contribution of the quaternary complex of FR-α, Fc-ARM2, anti-EGFR, and EGFR in this manuscript because we are currently incapable of isolating the quaternary complex.

Pooled IgG from donor sera for NK cell activation

Motivated by the observation that IgG1 mAb can be used for tumor cell killing in the Fc-ARM strategy, we sought to test whether antibody mixtures could also be used. A clinically used IgG mixture from donor sera, known as intravenous immunoglobulin (IVIG), as well as an affinity-purified IgG mixture were used. Upon recruitment by Fc-ARM2, both IgG products clearly induced ADCC against IGROV-1, whereas IgG products alone did not (Fig. 5A). Notably, the levels of ADCC induced by these two conditions were similar to that induced by Fc-ARM2 + anti-CD20 (IgG1 mAb). It would be because IgG1 has the highest blood concentration among all IgG subclasses, given that IgG1 is the most potent IgG subclass for ADCC induction. Taken together, the results suggested that endogenous antibodies circulating in the human body could be an effective resource for ADCC induction in the Fc-ARM strategy.

In vivo interactions between Fc-ARMs and human antibodies

Next, we tested whether Fc-ARMs could interact with antibodies in vivo. Considering the ease of synthesis compared with Fc-ARM2, we prepared a derivative of Fc-ARM1 labeled with sulfo-cyanine7 (Fc-ARM-Cy7, Fig. 5B and S10†). Because Fc-ARM2 did not work with mouse IgG (mIgG) (Fig. S11†), we pre-injected tumor-bearing mice with IVIG. Injected IVIG remains in the blood circulation for an extended period of time as a macromolecule. Thus, we hypothesized that pre-injection of IVIG into mice would enhance the blood circulation time and the tumor accumulation of the Fc-ARM. Mice received 20 mg of IVIG to mimic the blood concentration of IgG in humans. Then, 2 h after intraperitoneal injection of IVIG, IGROV-1 tumor-bearing BALB/c nu/nu mice were injected intraperitoneally with 5 nmol of Fc-ARM-Cy7. In vivo time-course imaging showed that IVIG significantly improved the blood retention time and tumor-targeted delivery of Fc-ARM-Cy7 (Fig. 5C and D). Ex vivo imaging 24 h after Fc-ARM-Cy7 injection showed that significantly higher amounts of Fc-ARM-Cy7 remained in
a range of dissected organs in the mice that received prior injection of IVIG (Fig. 5E and S12†). Considering that small molecules are readily removed from the systemic circulation through renal filtration, these data indicated that Fe-ARMs can hitchhike on human IgG antibodies and harness their pharmacokinetics in vivo, resulting in an enhanced blood circulation time and increased accumulation in tumors.

**Fig. 5** Fe-ARM effectively recruits IVIG for its enhanced blood retention time and tumor accumulation in vivo. (A) Two different products of IgG from human sera were compared with anti-CD20 mAb. IgG (100 nM) and Fe-ARM2 (10 nM) were added to 5000 cells per well of IGROV-1 cells. Then, 10 000–80 000 cells per well of KHYG-1/CD16a-158V cells were added and incubated for 16 h. LDH released from lysed cells was quantified (n = 3, mean ± SEM). Statistically significant differences between the “Fe-ARM2 + IgG” and “IgG only” groups were observed at all E/T ratios. (B) The molecular structure of Fe-ARM-Cy7. (C–E) 1 × 10⁶ of IGROV-1 cells were inoculated into the left side of the back of each BALB/c nu/nu mouse. When the tumor volume reached about 300 mm³, the mice received 20 mg of IVIG intraperitoneally. After 2 h, the mice received 5 nmol of Fe-ARM-Cy7 intraperitoneally. (C) in vivo fluorescence imaging of Fe-ARM-Cy7 at different time points was performed using an IVIS Lumina II. White arrows indicate tumors. Representative images from four mice in each group are shown. (D) Time-course quantification of the fluorescence signals from tumors (n = 4, mean ± SEM). (E) 24 h after Fe-ARM-Cy7 injection, organs were harvested and imaged ex vivo. Then, fluorescence signals were quantified (mean ± SEM). Two experimental repeats were performed. Statistical analyses were carried out using (A) one-way ANOVA with Tukey’s multiple comparison test or (D, E) a two-tailed Welch’s t test. *p < 0.05; **p < 0.01; N.S. = not significant.

**Fig. 6** Fe-ARM2 recruits IVIG to suppress IGROV-1 tumor growth. (A) The treatment schedule is shown. After inoculation of IGROV-1 cells, BALB/c nu/nu mice were injected intraperitoneally with 1 g kg⁻¹ of IVIG (0 and 9 days after tumor inoculation) and 4 mg kg⁻¹ of Fe-ARM2 (0, 3, 6, 9, 12, and 15 days after tumor inoculation). (B) The graph depicts the tumor volume until day 18 (n = 6 for untreated and IVIG and n = 5 for Fe-ARM2 and Fe-ARM2 + IVIG, mean ± SEM). (C) Individual growth curves for the IGROV-1 tumors shown in (B). (D) Body weight changes of mice during the treatment (mean ± SEM). Two experimental repeats were performed. Statistical analyses were carried out using one-way ANOVA with Tukey’s multiple comparison test (on day 12). *p < 0.05; **p < 0.01.

**Anti-tumor effect of the Fe-ARM strategy in vivo**

Finally, we tested the anti-tumor efficacy of the Fe-ARM strategy in vivo. Because there is crosstalk between human antibodies and mouse effector cells including mouse NK cells,⁴⁸ we hypothesized that the human IgG redirected to tumors can activate mouse NK cells and inhibit tumor growth. A summary of the treatment schedule is shown in Fig. 6A. Given that human IgG1 shows a blood half-life of approximately 10 days in mice,⁴⁹ IVIG (1 g kg⁻¹) was injected intraperitoneally into IGROV-1-bearing BALB/c nu/nu mice 0 and 9 days after tumor inoculation. Fe-ARM2 (4 mg kg⁻¹) was intraperitoneally administered to the mice 0, 3, 6, 9, 12, and 15 days after tumor inoculation. Fe-ARM2 + IVIG suppressed tumor growth compared with all of the other groups (Fig. 6B and C). Although the therapeutic efficacy was not that dramatic, this is presumably due to the lower capacity of human antibodies to activate murine NK cells compared with their murine counterparts.⁴⁸

Usage of immunologically humanized mice may enable us to evaluate the therapeutic potential of the Fe-ARM strategy more accurately. In addition, a stronger Fc-binder or a targeting ligand would enable the Fe-ARM to induce anti-tumor responses more strongly. In terms of the side effects, no abnormal weight loss of mice was observed during the treatment (Fig. 6D). Taken together, these data indicated that the Fe-ARM strategy can induce anti-tumor immune responses in vivo.

**Conclusions**

We have reported a novel class of antibody-recruiting small molecules (ARMs) that theoretically enables the recruitment of the majority of endogenous antibodies in the bloodstream for...
anti-tumor immune responses for the first time. Fe-ARMs recruited antibodies obtained from human sera to the FR-\(\alpha\)-cancer cell surface selectively and induced ADCC depending on the strength of their Fc affinity. Fe-ARMs successfully interacted with human antibodies in vivo, resulting in enhanced blood circulation and tumor accumulation. Furthermore, the Fe-ARM strategy suppressed the growth of IGROV-1 human ovarian adenocarcinoma in a mouse xenograft model. Fc affinity would provide the ARM strategy with efficient and robust opportunities to redirect endogenous antibodies to malignant cells. Therefore, our approach may lead to the re-emergence of ARMs as one of the promising modalities of cancer immunotherapy.

Author contributions

K. S., Y. M., T. M., and Y. K. conceived and designed the project. K. S., M. H., Y. M., and H. T. performed the experiments. K. S., T. M., and Y. K. analyzed the data. K. S., A. K., T. M., and Y. K. wrote the manuscript.

Ethical statement

All experiments using mice received approval from the Ethics Committee for Animal Experiments of Kyushu University and were in accordance with the guidelines of the Animal Care and Use Committee of Kyushu University.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was in part supported by Challenging Research (Exploratory) [Grant number: 18K19148] of MEXT, Japan. K. S. was supported by the Research Fellowship for Young Scientists (JSPS, 17J05032) and Advanced Graduate Course on Molecular Systems for Devices (Kyushu University). We thank Dr Y. Yonemitsu and Dr Y. Harada (Kyushu University) for fruitful discussions. We thank the Center for Advanced Instrumental and Educational Supports (Faculty of Agriculture, Kyushu University), and Dr M. Goto and Dr N. Kamiya (Kyushu University) for support with SPR experiments. We thank K. Fox, DPhil, from Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

References

1 A. M. Scott, J. D. Wolchok and L. J. Old, *Nat. Rev. Cancer*, 2012, 12, 278–287.
2 T. T. Hansel, H. Kropshofer, T. Singer, J. A. Mitchell and A. J. George, *Nat. Rev. Drug Discovery*, 2010, 9, 325–338.
3 G. M. Bartelds, C. A. Wijbrandts, M. T. Nurmohamed, S. Stapel, W. F. Lem, L. Aarden, B. A. Dijkmans, P. P. Tak and G. J. Wolbink, *Ann. Rheum. Dis.*, 2007, 66, 921–926.
4 P. J. McEnaney, C. G. Parker, A. X. Zhang and D. A. Spiegel, *ACS Chem. Biol.*, 2012, 7, 1139–1151.
5 K. Imai and A. Takaoka, *Nat. Rev. Cancer*, 2006, 6, 714–727.
6 C. R. Bertozzi and M. D. Bednarski, *J. Am. Chem. Soc.*, 1992, 114, 5543–5546.
7 C. R. Bertozzi and M. D. Bednarski, *J. Am. Chem. Soc.*, 1992, 114, 5543–5546.
8 C. R. Bertozzi and M. D. Bednarski, *J. Am. Chem. Soc.*, 1992, 114, 5543–5546.
9 Y. Lu, E. Sega and P. S. Low, *Int. J. Cancer*, 2005, 116, 710–719.
10 V. M. Krishnamurthy, L. J. Quinton, L. A. Estroff, S. J. Metallo, J. M. Isaacas, J. P. Mizgerd and G. M. Whitesides, *Biomaterials*, 2006, 27, 3663–3674.
11 V. R. Doppalapudi, N. Tryder, L. Li, T. Aja, D. Griffith, F.-F. Liao, G. Roxas, M. P. Ramprasad, C. Bradshaw and C. F. Barbas III, *Bioorg. Med. Chem. Lett.*, 2007, 17, 501–506.
12 C. B. Carlson, P. Mowery, R. M. Owen, E. C. Dykhuizen and L. L. Kiessling, *ACS Chem. Biol.*, 2007, 2, 119–127.
13 M. F. Perdomo, M. Levi, M. Sällberg and A. Vahlin, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, 105, 12515–12520.
14 M. K. O’Reilly, B. E. Collins, S. Han, L. Liao, C. Rillahan, P. I. Kitov, D. R. Bundle and J. C. Paulson, *J. Am. Chem. Soc.*, 2008, 130, 7736–7745.
15 C. G. Parker, R. A. Domaoal, K. S. Anderson and D. A. Spiegel, *J. Am. Chem. Soc.*, 2009, 131, 16392–16394.
16 R. P. Murelli, A. X. Zhang, J. Michel, W. L. Jorgensen and D. A. Spiegel, *J. Am. Chem. Soc.*, 2009, 131, 17090–17092.
17 M. Popkov, B. Gonzalez, S. C. Sinha and C. F. Barbas, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, 106, 4378–4383.
18 J. Gavrilyuk, H. Uehara, N. Otsubo, A. Hessell, D. R. Burton and C. F. Barbas III, *ChemBioChem*, 2010, 11, 2113–2118.
19 U. Wuehlner, J. I. Gavrilyuk and C. F. Barbas III, *Angew. Chem., Int. Ed.*, 2010, 49, 5934–5937.
20 A. Dubrowska, C. Kim, J. Elliott, W. Shen, T.-H. Kuo, D.-I. Koo, C. Li, T. Tuntland, J. Chang, T. Groessl, X. Wu, V. Gorney, T. Ramirez-Montagut, D. A. Spiegel, C. Y. Cho and P. G. Schultz, *ACS Chem. Biol.*, 2011, 6, 1223–1231.
21 R. T. Sheridan, J. Hudson, J. A. Hank, P. M. Sondel and L. L. Kiessling, *ChemBioChem*, 2014, 15, 1393–1398.
22 A. F. Rullo, K. J. Fitzgerald, V. Muthusamy, M. Liu, C. Yuan, M. Huang, M. Kim, A. E. Cho and D. A. Spiegel, *Angew. Chem., Int. Ed.*, 2016, 55, 3642–3646.
23 C. E. Jakobsche, C. G. Parker, R. N. Tao, M. D. Kolesnikova, E. F. Douglass Jr and D. A. Spiegel, *ACS Chem. Biol.*, 2013, 8, 2404–2411.
24 U. Galili, B. A. Machet, J. Buehler and S. B. Shohet, *J. Exp. Med.*, 1985, 162, 573–582.
25 H. Mitoma, T. Horiuichi, H. Tsukamoto, Y. Tamimoto, Y. Kimoto, A. Uchino, K. To, S. I. Harashima, N. Hatta and M. Harada, *Arthritis Rheuma*, 2008, 58, 1248–1257.
26 R. Vazquez-Lombardi, C. Loetsch, D. Zinkl, J. Jackson, P. Schofield, E. K. Deenick, C. King, T. G. Phan, K. E. Webster, J. Sprent and D. Christ, *Nat. Commun.*, 2017, 8, 15373.
27 H.-S. Dai, N. Griffin, C. Bolyard, H. C. Mao, J. Zhang, T. P. Cripe, T. Suenaga, H. Arase, I. Nakano, E. Chiocca, B. Kaur, J. Yu and M. A. Caligiuri, *Immunity*, 2017, 47, 159–170.

28 W. L. DeLano, M. H. Ultsch and J. A. Wells, *Science*, 2000, 287, 1279–1283.

29 K. Sasaki, Y. Miyashita, D. Asai, D. Funamoto, K. Sato, Y. Yamaguchi, Y. Mishima, T. Iino, S. Takaishi, J. Nagano, A. Kishimura, T. Mori and Y. Katayama, *MedChemComm*, 2018, 9, 783–788.

30 Y. Jung, H. J. Kang, J. M. Lee, S. O. Jung, W. S. Yun, S. J. Chung and B. H. Chung, *Anal. Biochem.*, 2008, 374, 99–105.

31 M. French and G. Harrison, *Clin. Exp. Immunol.*, 1984, 56, 473–475.

32 M. Klouche, A. R. Bradwell, D. Wilhelm and H. Kirchner, *Clin. Chem.*, 1995, 41, 1475–1479.

33 B. Li, L. Zhao, H. Guo, C. Wang, X. Zhang, L. Wu, L. Chen, Q. Tong, W. Qian, H. Wang and Y. Guo, *Blood*, 2009, 114, 5007–5015.

34 G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat and H. Watier, *Blood*, 2002, 99, 754–758.

35 Y. Gong, L. Zhang, J. Li, S. Feng and H. Deng, *Bioconjugate Chem.*, 2016, 27, 1569–1573.

36 C. Chen, J. Ke, X. E. Zhou, W. Yi, J. S. Brunzelle, J. Li, E.-L. Yong, H. E. Xu and K. Melcher, *Nature*, 2013, 500, 486–489.

37 E. I. Sega and P. S. Low, *Cancer Metastasis Rev.*, 2008, 27, 655–664.

38 E. F. Douglass Jr, C. J. Miller, G. Sparer, H. Shapiro and D. A. Spiegel, *J. Am. Chem. Soc.*, 2013, 135, 6092–6099.

39 M. J. Barth, C. Mavis, M. S. Czuczman and F. J. Hernandez-Illizaliturri, *Clin. Cancer Res.*, 2015, 21, 4391–4397.

40 Y. Mishima, Y. Terui, Y. Mishima, R. Kuniyoshi, S. Matsusaka, M. Mikuniya, K. Kojima and K. Hatake, *Int. Immunol.*, 2012, 24, 477–483.

41 G. Alter, J. M. Malenfant and M. Altfeld, *J. Immunol. Methods*, 2004, 294, 15–22.

42 M. P. Velders, C. M. van Rhijn, E. Oskam, G. J. Fleuren, S. O. Warnaar and S. V. Litvinov, *Br. J. Cancer*, 1998, 78, 478–483.

43 G. Romain, V. Senyukov, N. Rey-Villamizar, A. Merouane, W. Kelton, I. Liadi, A. Mahendra, W. Charab, G. Georgiou, B. Roysam, D. A. Lee and N. Varadarajan, *Blood*, 2014, 124, 3241–3249.

44 S. M. Lippow, K. D. Wittrup and B. Tidor, *Nat. Biotechnol.*, 2007, 25, 1171–1176.

45 M. Brüggemann, G. T. Williams, C. I. Bindon, M. R. Clark, M. R. Walker, R. Jefferis, H. Waldmann and M. S. Neuberger, *J. Exp. Med.*, 1987, 166, 1351–1361.

46 J. T. Andersen, M. B. Daba, G. Berntzen, T. E. Michaelisen and I. Sandlie, *J. Biol. Chem.*, 2010, 285, 4826–4836.

47 A. Gonzalez-Quintela, R. Alende, F. Gude, J. Campos, J. Rey, L. Meijide, C. Fernandez-Merino and C. Vidal, *Clin. Exp. Immunol.*, 2008, 151, 42–50.

48 M. B. Overdijk, S. Verploegen, A. Ortiz Buijsse, T. Vink, J. H. Leusen, W. K. Bleeker and P. W. Parren, *J. Immunol.*, 2012, 189, 3430–3438.

49 S. B. Petkova, S. Akilesh, T. J. Sproule, G. J. Christianson, H. Al Khabbaz, A. C. Brown, L. G. Presta, Y. G. Meng and D. C. Roopenian, *Int. Immunol.*, 2006, 18, 1759–1769.